Prost ate cancer is the third-leading cause of cancerrelated deaths and the most frequently diagnosed cancer among men in the Western world (1) . There is a great need for an imaging technique that provides adequate staging of patients with this disease. A promising approach to cancer diagnosis is the use of radiolabeled receptor-binding peptides. It has been shown that prostate tumors overexpress the gastrin-releasing peptide receptor (GRPR) (2) (3) (4) (5) (6) . GRPRs are expressed in primary prostate cancer, invasive prostate carcinoma, and prostatic intraepithelial neoplasms at high density, whereas normal prostate tissue and benign prostate hyperplasia (BPH) are predominantly GRPR-negative (2) . These findings suggest that the GRPR represents an ideal molecular target for radiolabeled GRPR ligands for diagnosis and staging of prostate cancer.
Bombesin (BBN) is the 14-amino acid amphibian peptide analog of the 27-amino acid mammalian gastrin-releasing peptide (GRP). BBN and GRP share a homologous 7-amino acid amidated C-terminus, Trp-Ala-Val-Gly-His-Leu-Met-NH 2 , which is necessary for binding to the GRPR. Because GRP suffers from poor in vivo stability, developments have focused on BBN analogs. Synthetic BBNs are truncated versions of BBNs containing the sequence or a full-length 14-amino acid sequence in which one or more amino acids have been replaced. The C-terminus of BBN is required for high-affinity binding and biologic potency (7) . Therefore, the N-terminus of BBN is usually modified for labeling the analogs with radioisotopes. A variety of BBN analogs has been developed and labeled with various radionuclides, such as 99m Tc and 111 In, for SPECT (8) and 64 Cu, 68 Ga, or 86 Y for PET (9, 10) . 18 F is the most widely used radionuclide in PET. 18 F has excellent characteristics for peptide-based receptor imaging studies: the half-life (109.7 min) matches the pharmacokinetics of most peptides, and the low positron energy of 635 keV results in a short penetration range in tissue and excellent imaging resolution (11) . Several methods have been developed to label peptides with 18 F. However, in general these methods are laborious and require a multistep synthesis. Recently, McBride et al. reported a facile method wherein 18 F is first attached to aluminum as Al 18 F, which is then complexed in a chelating agent attached to the peptide, forming a stable Al 18 F-chelate peptide complex in an efficient 1-pot process (12) .
Several studies have indicated that the DOTA-conjugated BBN analog, DOTA-8-Aoc-BBN(7-14)NH 2 , satisfies inherent in vitro and in vivo requirements for radiopharmaceutical development (13) (14) (15) . However, the DOTA chelator in the studies of Rogers et al. (13) showed demetallation of 64 Cu. Therefore, Prasanphanich et al. conjugated the NOTA chelator to 8-Aoc-BBN(7-14)NH 2 to produce a kinetically inert BBN conjugate (16) .
As shown previously, NOTA-conjugated peptides can be labeled with 18 F using the Al 18 F method (17) (18) (19) . Here, we describe the 18 F labeling of NOTA-8-Aoc-BBN(7-14)NH 2 , using the new 1-pot, 1-step, labeling method. The in vitro affinity and the in vivo tumor targeting characteristics of 18 F-labeled NOTA-8-Aoc-BBN(7-14)NH 2 were determined and compared with those of the 68 Ga-labeled counterpart.
MATERIALS AND METHODS
Synthesis of NOTA-Conjugated BBN Derivative 8-Aoc-BBN(7-14)NH 2 The BBN derivative was synthesized using Fmoc-based solidphase peptide synthesis as described previously (16) . The structural formula of NOTA-8-Aoc-BBN(7-14)NH 2 is shown in ½Fig: 1 
Radiolabeling
Labeling with 18 F. NOTA-8-Aoc-BBN(7-14)NH 2 was radiolabeled with 18 F as described by Laverman et al. (17) . Briefly, a Chromafix cartridge with 2-6 GBq of 18 F (BV Cyclotron VU) was washed with 3 mL of metal-free water. 18 F was eluted from the cartridge with 100 mL of 0.4 M KHCO 3 . The pH of the eluate was adjusted to 4.1 with 5 mL of metal-free glacial acetic acid, and 2-40 mL of 2 mM AlCl 3 in 0.1 M sodium acetate buffer (pH 4.1) were added. Finally, 80 mL of this Al 18 F solution was added to 400 mL of MeCN and 20 mL of NOTA-8-Aoc-BBN(7-14)NH 2 (5 mg/mL) in 0.5 M sodium acetate, pH 4.1. The reaction mixture was heated at 100°C for 15 min. The radiolabeled peptide was purified by reversedphase high-performance liquid chromatography (RP-HPLC) using the gradient as in the "Quality Control" section. Fractions containing 18 F-NOTA-8-Aoc-BBN(7-14)NH 2 were collected and diluted 10-fold with H 2 O and purified on an Oasis HLB 1-cm 3 (10-mg) cartridge (Waters) to remove acetonitrile and trifluoroacetic acid. In brief, the fraction was applied on the cartridge, and the cartridge was washed with 3 · 1 mL of H 2 O. The radiolabeled peptide was eluted with 200 mL of EtOH/H 2 O (1:1, v/v). For injection into mice, the peptide was diluted with 0.5% bovine serum albumin in 0.9% NaCl.
Labeling with 68 Ga. 68 Ga was obtained from a 1,850-MBq 68 Ge/ 68 Ga generator (IGG-100, Eckert & Ziegler), where 68 Ge was attached to a TiO 2 -based column. The 68 Ga was eluted with 0.1 M HCl (Ultrapure; J.T. Baker) using an Econo Pump (Bio-Rad) at 1 mL/min. Five 1-mL fractions were collected, and an aliquot of the second fraction was used for labeling the peptide.
68 Ga-labeled NOTA-8-Aoc-BBN(7-14)NH 2 was prepared by adding 20 mL of 2.5 M HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid) solution to 5 mL of the peptide dissolved in 2.5 M HEPES (2 mg/mL). Then, the second fraction from the 68 Ge/ 68 Ga generator (315-365 MBq) was added. After 10 min at 95°C
, the 68 Ga-labeled peptide was purified on an Oasis HLB (30-mg) cartridge (Waters). After the sample was applied to the cartridge, the cartridge was washed with 3 · 1 mL of H 2 O and eluted with 200 mL of EtOH/H 2 O (1:1, v/v).
Quality Control. The radiolabeled preparations were analyzed by RP-HPLC on an Agilent 1200 system (Agilent Technologies). A C18 column (Onyx monolithic, 4.6 mm · 100 mm; Phenomenex) was used at a flow rate of 3 mL/min with the following buffer system: buffer A, 0.1% v/v trifluoroacetic acid in H 2 O; buffer B, 0.1% v/v trifluoroacetic acid in acetonitrile; and a gradient of 80% buffer A at 0-5 min and 80% buffer A to 76% buffer A at 5-20 min. The radioactivity of the eluate was monitored using an in-line NaI radiodetector (Raytest GmbH). Elution profiles were analyzed using Gina-star software (version 2.18; Raytest GmbH). For injection into mice, the peptide was diluted to less than 10% (v/v) ethanol with 0.5% (w/v) bovine serum albumin in 0.9% NaCl.
Octanol/Water Partition Coefficient
To an Eppendorf tube filled with 0.5 mL of the radiolabeled peptide in phosphate-buffered saline (pH 7.4), 0.5 mL of octanol was added. After the tube was vigorously stirred by a vortex mixer for 2 min at room temperature, the 2 layers were separated by centrifugation (100g, 5 min). Samples of 100 mL were taken from each layer, radioactivity was measured in a well-type g-counter (Wallac Wizard 3$; PerkinElmer), and log P values were calculated (n 5 3).
Competitive Cell-Binding Assay
The PC-3 human prostate cancer cell line was cultured in RPMI 1640 medium supplemented with 10% (v/v) fetal calf serum. Cells were grown in tissue culture flasks at 37°C in a humidified atmosphere containing 5% CO 2 and routinely passed using 0.25% trypsin/ ethylenediaminetetraacetic acid.
Binding affinities toward the GRPR for nat Ga-, Al nat F-, and nonlabeled NOTA-8-Aoc-BBN(7-14)NH 2 were determined in a competitive binding assay on PC-3 tumor cells, using 111 In-NOTA-8-Aoc-BBN(7-14)NH 2 as a tracer. PC-3 cells were seeded into 6-well plates at 3 · 10 5 cells per well and cultured until confluency. On the day of the assay, cells were washed with binding buffer (RPMI, 0.5% bovine serum albumin). Subsequently, binding buffer (1.5 mL), nat Ga-, Al nat F-, or nonlabeled NOTA-8-Aoc-BBN(7-14)NH 2 in a range of 0.1 to 300 nM and 200 Bq of 111 In-NOTA-8-Aoc-BBN (7-14)NH 2 were added to each well. After incubation for 3 h, medium was removed. Then, cells were washed with binding buffer and extracted from the wells, and cell-associated radioactivity was determined in a g-counter. For the complexation of NOTA-8-Aoc-BBN (7-14)NH 2 with nat Ga 31 , the peptide was dissolved in an aqueous solution (2.5 M HEPES; 1 mg/mL) and a 3-fold molar excess of nat Ga(NO 3 
Biodistribution Studies
Male nude BALB/c mice (6-8 wk old) were injected subcutaneously in the right flank with 0.2 mL of a PC-3 cell suspension of 1.5 · 10 7 cells/mL (66% RPMI, 33% Matrigel [BD Biosciences]). Two weeks after inoculation of the tumor cells, mice were injected intravenously with the 18 F-or 68 Ga-labeled NOTA-8-Aoc-BBN(7-14)NH 2 (,1 mg). Mice were killed by CO 2 asphyxiation 1 h after injection (5-6 mice per group). Blood, tumor, and the major organs and tissues were collected, weighed, and counted in a g-counter. The percentage injected dose per gram (%ID/g) was determined for each sample.
The receptor-mediated localization of the radiolabeled peptide was investigated by determining the biodistribution of the 18 
Small-Animal PET/CT
Mice with subcutaneous PC-3 tumors were injected intravenously with 2 MBq of 18 F-labeled NOTA-8-Aoc-BBN(7-14)NH 2 . One hour after the injection of the radiolabeled peptide, mice were scanned on an animal PET/CT scanner (Inveon; Siemens Preclinical Solutions) with an intrinsic spatial resolution of 1.5 mm (11). The animals were placed supine in the scanner. PET emission scans were acquired over 20-25 min, followed by a CT scan for anatomic reference (spatial resolution, 113 mm; 80 kV; and 500 mA). Scans were reconstructed using Inveon Acquisition Workplace software (version 1
Statistical Analysis
All mean values are given with SD. Statistical analysis was performed using a Welch corrected unpaired Student t test or 1-way ANOVA using GraphPad InStat software (version 3.06; GraphPad Software). The level of significance was set at P less than 0.05.
RESULTS

Radiolabeling
RP-HPLC analysis indicated that the radiochemical purity of the 18 F-or 68 Ga-labeled NOTA-8-Aoc-BBN(7-14)NH 2 preparations used in these experiments always exceeded 95%. Radio-HPLC chromatograms of 18 F-and 68 Ga-labeled NOTA-Aoc-BBN(7-14)NH 2 are shown in ½Fig: 2 Figure 2 . Al 18 F-NOTA-Aoc-BBN(7-14)NH 2 had a retention time of 16.3 min and eluted at 23% of buffer B. 68 Ga-NOTA-Aoc-BBN(7-14)NH 2 had a 12.7-min retention time and eluted at 22% of buffer B.
Octanol/Water Partition Coefficient
To establish lipophilicity of the 18 F-and 68 Ga-labeled NOTA-8-Aoc-BBN(7-14)NH 2 , the octanol/water partition coefficients were determined. The log P octanol/water value for the 18 F-labeled BBN analog was 21.47 6 0.05. The 68 Ga-labeled analog was more hydrophilic, with a log P octanol/water value of 21.98 6 0.03. 
Competitive Binding Assay
The affinity of Al nat F-, nat Ga-, and nonlabeled NOTA-8-Aoc-BBN(7-14)NH 2 for GRPR was determined in a competitive binding assay. The results of these assays are summarized in ½Fig: 3 Figure 3 . Binding of 111 In-labeled BBN peptide to GRPR was displaced by nat Ga-, Al nat F-, and nonlabeled NOTA-8-Aoc-BBN(7-14)NH 2 in a concentration-dependent manner. The IC 50 values of the Al nat F-, nat Ga-, and nonlabeled compounds were not significantly different and in the subnanomolar range (0.28 6 0.15, 0.41 6 0.15, and 0.37 6 0.15 nM, respectively), indicating high binding affinity for the GRPR.
Biodistribution Studies
The results of the biodistribution studies of both 18 F-and 68 Ga-labeled NOTA-8-Aoc-BBN(7-14)NH 2 are summarized in ½Fig: 4 Figure 4 . NOTA-8-Aoc-BBN(7-14)NH 2 radiolabeled with either 18 F or 68 Ga cleared rapidly from the blood, in which levels of both tracers were below 0.07 %ID/g at 1 h after injection. Tumor uptake of 18 F-labeled NOTA-8-Aoc-BBN (7-14)NH 2 was significantly higher than that of 68 Ga-labeled NOTA-8-Aoc-BBN(7-14)NH 2 (2.15 6 0.55 vs. 1.24 6 0.26 %ID/g, respectively; P , 0.05). In addition to tumor uptake, 18 F-labeled NOTA-8-Aoc-BBN(7-14)NH 2 had significantly higher uptake in the pancreas than did the 68 Ga-labeled analog (27.09 6 12.77 %ID/g vs. 5.93 6 2.10 %ID/g; P , 0.01).
The coinjection of an excess of unlabeled NOTA-8-Aoc-BBN(7-14)NH 2 (50 mg) along with 18 F-or 68 Ga-labeled NOTA-8-Aoc-BBN(7-14)NH 2 resulted in a significantly reduced radioactivity concentration in the tumor, indicating that the major fraction of the uptake of radiolabeled NOTA-8-Aoc-BBN(7-14)NH 2 in the tumor was GRPR-mediated. Also, GRPR-specific uptake in the pancreas for 18 F-and 68 Ga-labeled NOTA-8-Aoc-BBN(7-14)NH 2, in the presence of an excess of nonradiolabeled peptide showed significant reduction in accumulation of the tracer (0.43 6 0.08 and 0.21 6 0.09 %ID/g).
Small-Animal PET/CT
Fused PET and CT images are shown in ½Fig: 5 Figure 5 . PET scans were in line with the biodistribution data. PC-3 tumors could be clearly visualized. However, there was considerable accumulation and retention in other organs such as the kidneys, liver, and intestines. In addition, uptake in the pancreas was relatively high and appeared to be specific. As a whole, uptake in the abdominal cavity was relatively high and is not entirely unexpected.
DISCUSSION
The diagnostic accuracy of metabolic PET tracers, such as 18 F-FDG, 18 F-or 11 C-choline, and 11 C-acetate, for imaging prostate cancer is limited, because most prostate tumor lesions are characterized by a low metabolic activity (20) . The discovery of GRPR overexpression in prostate cancer disease has led to the development and application of radiolabeled BBN derivatives for imaging and staging of prostate cancer using SPECT or PET. Here, the feasibility of using an 18 F-labeled BBN analog for radionuclide imaging of GRPR expression with PET was investigated. The NOTA-conjugated BBN analog was radiolabeled with 18 F, using the new chelator-based method developed by McBride et al. (12) . The in vitro and in vivo characteristics of this 18 F-labeled peptide were directly compared with those of the 68 Ga-labeled analog. 
RGB
To radiolabel NOTA-conjugated BBN peptide with 18 F, we used our optimized 1-pot method for labeling peptides with 18 F as described recently (17) . First, 18 F 2 was complexed with Al 31 , and subsequently the Al 18 F complex was chelated by NOTA. It is still unclear which aluminum-fluoride complex is formed, but because the formation of Al 18 F is performed at pH 4.1, we believe that the form in sodium acetate buffer is probably AlF 2+ . In addition, the molar ratio of aluminum to 18 F is such that it is unlikely that any AlF 2 + or AlF 3 is formed (21) .
The 18 F-labeled peptide was slightly more lipophilic than the 68 Ga-labeled BBN analog, as indicated by their log P values (21.98 6 0.03 and 21.47 6 0.05, respectively). This difference could be due to the dianionic NOTA chelator, which stabilizes the 12 charge of the Al 18 F-complex but not the 13 charge of the 68 Ga atom, resulting in an overall 11 charge for the 68 Ga-NOTA complex. However, the presence of counter ions could play a role as well.
In a competitive binding assay using GRPR-expressing PC-3 cells, the IC 50 values of the nonlabeled and cold labeled analogs were not significantly different and were in the subnanomolar range. Prasanphanich et al. also determined the IC 50 value of NOTA-8-Aoc-BBN(7-14)NH 2 , and in this assay the binding affinity of their compound was somewhat lower than the binding affinity as determined in our assay (3.1 6 0.5 vs. 0.37 6 0.2 nM) (16) . Although they also used PC-3 cells in their assay, their tracer was 125 I-Tyr 4 -BBN, whereas in our assay the 111 In-NOTA-8-Aoc-BBN(7-14)NH 2 ligand was used as the displacement radioligand.
In the subcutaneous PC-3 xenograft model, the tumor uptake of 18 F-labeled NOTA-8-Aoc-BBN(7-14)NH 2 was significantly higher than that of 68 Ga-labeled NOTA-8-Aoc-BBN(7-14)NH 2 at 1 h after injection (2.15 6 0.55 vs. 1.24 6 0.26 %ID/g, respectively; P , 0.05). Both tracers showed specific tumor uptake in PC-3 tumors: the coinjection of an excess of unlabeled NOTA-8-Aoc-BBN(7-14)NH 2 resulted in a significantly lower tumor uptake of 68 Ga-NOTA-8-Aoc-BBN(7-14)NH 2 and 18 F-NOTA-8-Aoc-BBN(7-14)NH 2 (0.26 6 0.15 and 0.88 6 0.12 %ID/g, respectively). Several tissues in mice express the GRPR, including the small intestine, large intestine, and pancreas (22) . In our study, specific uptake of 68 Ga-NOTA-8-Aoc-BBN(7-14)NH 2 and 18 F-NOTA-8-Aoc-BBN(7-14)NH 2 was found in the colon and pancreas, indicating that the accumulation of these tracers in these tissues is at least partly GRPR-mediated. 18 F-and 68 Ga-labeled NOTA-8-Aoc-BBN(7-14)NH 2 cleared rapidly from the blood, resulting in high tumor-to-blood ratios at 1 h after injection (49.51 6 22.94 and 25.06 6 10.55, respectively).
The uptake of the 64 Cu-labeled NOTA-8-Aoc-BBN (7) (8) (9) (10) (11) (12) (13) (14) conjugate in PC-3-bearing mice (3.59 6 0.70 % ID/g, 1 h after injection) was similar to the tumor uptake for our radiolabeled compounds (2.15-1.24.%ID/g, 1 h after injection) (16) . However, Lears et al. recently reported in this tumor model a tumor uptake as high as 13.0 %ID/g at 1 h after injection using 64 Cu-labeled SarAr-SA-Aoc-BBN(7-14) (23) . This compound has an additional linker and is labeled with another radionuclide via a different chelator, and each of these parameters could have caused the higher uptake of this tracer in the tumor. However, in our experiments we observed that the tumor uptake can vary largely from one experiment to the other. Even within the same experiment, the uptake of the radiolabeled BBN analog in the PC-3 tumor varied considerably.
To select the best ligand for clinical evaluation, Schroeder et al. performed a comparative study using 5 radiolabeled BBN analogs under identical experimental conditions (24) . In previous studies in PC-3-bearing mice, 67 Ga-PESIN, 177 Lu-AMBA, and 99m Tc-demobesin-1 showed tumor uptake of 14.8, 6.4, and 16.2 %ID/g, respectively (9, (25) (26) (27) (28) . Variation in amounts of peptides, mouse strain (species, sex, and weight), tumor cells (passage number, culture conditions) used, tumor size, and vascularization of the tumor may all be factors that affect tumor uptake and tumor-to-non-tumor ratios. On the basis of these data, the authors selected 99m Tcdemobesin-1 as the bombesin analog with optimal characteristics for prostate cancer imaging. This study of the group in Rotterdam demonstrated that the characteristics of radiolabeled BBN analogs can be appreciated only in a direct comparative study.
Overall, the biodistribution of 18 F-NOTA-8-Aoc-BBN (7-14)NH 2 in mice with subcutaneous PC-3 xenografts was similar to that of 68 Ga-NOTA-8-Aoc-BBN(7-14)NH 2 , indicating that labeling the analog with Al 18 F did not affect the in vivo characteristics of the bombesin derivative.
The Al 18 F method is a fast (45 min) radiofluorination strategy and does not affect the pharmacokinetics of the bombesin peptide. The commonly used methodology for efficient 18 F- labeling of peptides consists of 2 steps: first the preparation of an 18 F-labeled synthon (prosthetic groups), which is subsequently conjugated to the peptide or the protein. In general, this fluorination is based on a nucleophilic substitution that requires laborious azeotropic drying of the 18 F-fluoridekryptofix complex. The total synthesis and formulation time for these methods ranges between 1 and 3 h, with most of the time dedicated to the HPLC purification of the labeled peptides to obtain the carrier-free tracer required for in vitro and in vivo experiments. We also had to purify our 18 F-labeled peptide with HPLC to obtain a high-specific-activity preparation. Recently, McBride et al. have shown that the AlF method can be further optimized using other chelators (19, 29) . They developed a 1-pot method that provides a high labeling efficiency and specific activity with no more than only solid-phase extraction purification needed before formulation for injection. Because the Al 18 F-method is based on a chelator-derivatized peptide, this labeling method is easy and versatile.
CONCLUSION
The Al 18 F method combines the ease of chelator-based radiolabeling methods with the advantages of 18 F, such as half-life, availability, and positron energy. The 18 F-labeled NOTA-8-Aoc-BBN(7-14)NH 2 could be synthesized in less than 45 min without the need to synthesize a synthon. The results of the biodistribution study of the 18 F-and 68 Ga-labeled BBN peptide show that the AlF method does not affect the in vivo behavior of the analog. The 18 F-labeled BBN peptide is a suitable ligand for the noninvasive visualization of GRPR expression in vivo.
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